1. Home
  2. ICON vs RDHL Comparison

ICON vs RDHL Comparison

Compare ICON & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ICON

Icon Energy Corp.

HOLD

Current Price

$1.02

Market Cap

3.5M

Sector

N/A

ML Signal

HOLD

RDHL

Redhill Biopharma Ltd.

HOLD

Current Price

$0.50

Market Cap

3.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICON
RDHL
Founded
2023
2009
Country
Greece
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5M
3.3M
IPO Year
2023
2012

Fundamental Metrics

Financial Performance
Metric
ICON
RDHL
Price
$1.02
$0.50
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
20.4K
★ 2.5M
Earning Date
02-24-2026
04-27-2026
Dividend Yield
★ 4754.20%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$22.33
$381.91
Revenue Next Year
$23.70
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$0.52
52 Week High
$4.23
$2.79

Technical Indicators

Market Signals
Indicator
ICON
RDHL
Relative Strength Index (RSI) 52.31 34.51
Support Level $0.84 N/A
Resistance Level $1.08 $1.07
Average True Range (ATR) 0.06 0.04
MACD 0.01 -0.01
Stochastic Oscillator 65.22 0.00

Price Performance

Historical Comparison
ICON
RDHL

About ICON Icon Energy Corp.

Icon Energy Corp is a growth-oriented shipping company providing seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels. The company generates its revenues by chartering its vessels to regional and international dry bulk operators, commodity traders and end users. The cargos carried by the company are Grains, Minerals, Iron Ore, Coal and Bauxite.

About RDHL Redhill Biopharma Ltd.

RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.

Share on Social Networks: